Effect of interleukin 2 on intractable herpes virus infection and chronic eczematoid dermatitis in a patient with Wiskott-Aldrich syndrome
Recombinant interleukin 2 (rIL2) was administered to a patient with Wiskott-Aldrich syndrome for the treatment of an intractabel facial herpetiforme lesion. This treatment appeared to be effective in suppressing the virus activity. At the same time, a transient improvement of the chronic eczematoid dermatitis was observed. During rIL2 administration, the CD3+ and CD4+ subsets of peripheral blood lymphocytes increased in number. These changes might play an important role in the induction of anti-viral immunity and in the improvement of dermatits.
Key wordsRecombinant IL2 Wiskott-Aldrich syndrome Atopic dermatitis Herpes virus infection
recombinant Interleukin 2
Unable to display preview. Download preview PDF.
- 2.Chien CH, Hsieh K-H (1990) Interleukin-2 immunotherapy in children. Pediatr 86:937–943Google Scholar
- 9.Rosenberg SA, Lotze MT, Muul LM, Chnag AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889–897PubMedGoogle Scholar